Pulmonary Arterial Hypertension: Advances in Diagnosis and Treatment is organized by Healio.
Release Date: October 11, 2023
Expiration Date: October 10, 2024
Activity Description:
Pulmonary arterial hypertension (PAH) is characterized by pulmonary vascular remodeling, and it often has a heterogeneous presentation that leads to delays in diagnosis and treatment. A major goal of the diagnostic approach is early suspicion of disease in high-risk patients to ensure timely referral to pulmonary hypertension centers and identification of underlying comorbidities to aid in classification, testing, risk assessment, and treatment. Despite the number of available FDA-approved therapies, many patients do not achieve low-risk status, and their long-term prognosis remains poor. One of the emerging therapies for PAH includes a novel agent that modulates transforming growth factor-?; phase 1 and 2 trials have shown significant improvement in exercise capacity and key secondary outcome measures compared with placebo. Pulmonologists, cardiologists, and other healthcare professionals should also be able to implement strategies for shared decision-making amongst a multidisciplinary team. In this CE activity, expert faculty will review recommended diagnostic strategies, tests, and risk assessments for PAH; evaluate the safety and efficacy of current and emerging therapies; and describe approaches for multidisciplinary management of patients with PAH.
Learning Objective:
Upon successful completion of this activity, participants should be better able to:
• Summarize the clinical manifestations of and recommended methods for diagnosing patients with PAH.
• Review the recommended tests and risk assessment procedures that influence treatment regimens for patients with PAH.
• Evaluate the mechanism of action, safety, and efficacy of current and emerging therapeutic agents for treating patients with PAH.
• Describe the utility of multidisciplinary care teams and shared decision-making for improving outcomes for patients with PAH.